Form 4: Director Martin Dewhurst Receives Turn Therapeutics Options

Director Martin William Dewhurst was granted 71,666 stock options in Turn Therapeutics Inc. as part of the company's 2025 Omnibus Incentive Plan.

Summary

• Director Martin William Dewhurst received a grant of 71,666 stock options on June 4, 2026.
• The options have an exercise price of $5.75 per share.
• The options are set to expire on June 4, 2036.
• Vesting occurs in twelve equal monthly installments starting June 30, 2026, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices rather than a change in company strategy or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standardized vesting schedule encourages retention of key leadership.

Negatives

• Granting of stock options results in potential future dilution for existing shareholders.

Risks

• Vesting is subject to the continued service of the director, creating a dependency on personnel retention.
• The value of the options is dependent on the future market performance of TTRX common stock.

Future Outlook

The options vest over a one-year period, indicating a short-to-medium term incentive structure for the director's continued service.

Management Comments

• The option grant is subject to the terms and conditions of the Issuer's 2025 Omnibus Incentive Plan.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice to ensure leadership remains incentivized to drive company growth and align with shareholder interests.

Comparison to Industry Standards

• The use of a 12-month vesting schedule for director options is consistent with standard equity incentive practices in the biotechnology and pharmaceutical sectors.
• The exercise price reflects the company's valuation at the time of grant, aligning with standard SEC disclosure requirements for derivative securities.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Commencement of monthly vesting installments on June 30, 2026.

Key Dates

Keywords

Turn Therapeutics, TTRX, Stock Options, Director Compensation, Insider Transaction, Form 4